when

Latest
Archive

by source

All Sources
Sources Page

department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

by stage

Marketed
Phase 3
Phase 2
Phase 1
Preclinical

browse

Most catalysts
Recently active
All drugs →
Companies
Patent cliff

what

Trial readouts
PDUFA dates
Approvals
Earnings

when

Upcoming
Month grid
Recently passed

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Jobs
News
Drugs
Calendar
Companies

Hubs

Topics
Patent cliff
Publications
Readouts

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
search

Pluvicto · news · pharmadog

← back to Pluvicto

News mentioning Pluvicto

34 stories

6d3 steps for taking on Novartis in radiopharma: Curium up firstbiospace

12dNovartis bets up to $900M for radioligand therapy from China’s BoomRaybiospace

13dNovartis secures new radioligand in $900M deal as competition strengthensfiercebiotech

14dWestern licensing deals for Chinese radioligand therapies to jump in 2027, Sleuth forecastsbiospace

14dSleuth forecasts 2027 jump in Western license deals for Chinese radioligand therapiesbiospace

14dTelix buys ITM for $1.65B in ‘supercritical’ radiopharma M&Abiospace

14dTelix buys ITM in bid to create a ‘radiopharmaceutical powerhouse’biopharma dive

14dAnalysts ‘extremely bullish’ as Telix beams into Novartis’ territory with $1.6B ITM acquisitionfiercebiotech

24dNovartis’ board faces investor scrutiny after M&A misfires and R&D flopsbiospace

Aug 31, 26A winner, a loser, and a mid-stage signal from a major cardiology research conferencestat

Aug 25, 26Preparing for Novartis showdown, Curium touts value of radiopharma supply resiliencybiospace

Aug 10, 26ITM neuroendocrine tumor drug spurned by FDA over manufacturing qualmsfiercebiotech

Aug 4, 26J&J pharma leader to retire; Krystal slumps on gene therapy missbiopharma dive

Aug 3, 26FDA expands Pluvicto label, making it available to most metastatic prostate cancer patientsendpoints

Aug 3, 26Curium strikes up to $8B deal for radiopharma rival Lantheusfiercebiotech

Aug 3, 26Recon: AstraZeneca, BMS discuss merger; FDA broadens indication for Novartis’ Pluvictoraps

Jul 22, 26Novartis scraps mid-stage radiopharma asset as Pluvicto soarsbiospace

Jul 21, 26Novartis climbs on upbeat drug sales as key readouts loombiopharma dive

Jul 21, 26Novartis stays 'geography-agnostic' in dealmaking amid flurry of China dealsbiospace

Jul 21, 26Novartis drops phase 2 radioligand therapy, but CEO’s commitment to modality ‘unchanged’fiercebiotech

Jul 15, 26Radiopharma maker AdvanCell hauls in $315M for Pluvicto challengerendpoints

Jul 6, 26Novartis to acquire ADC developer in a deal worth up to $1.5Bbiopharma dive

Jun 8, 26Precision under pressure: Logistic solutions for nuclear medicine scalabilitybiopharma dive

Jun 4, 26Opinion: Grail’s multi-cancer early detection trial was negative. But as an oncologist, I see more to this storystat

Jun 3, 26STAT+: Alnylam to partner with Inceptive Nucleics for AI foundation models for RNAi therapeuticsstat

Jun 3, 26STAT+: HaloMD faces lawsuit alleging No Surprises Act middleman used ‘sham letter,’ misleading datastat

Jun 3, 26STAT+: Legend Biotech emerged as a rare market winnerstat

Jun 3, 26Opinion: The medical-billing AI arms race between providers and insurancestat

Jun 3, 26STAT+: Trump’s Medicaid work requirements have an unwelcome surprise for some states and patientsstat

Jun 3, 26Senior NIH scientist, research fellow charged with bringing deactivated mpox virus into U.S.stat

← prevpage 1 of 2next →